DCOY
Decoy Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.17
+0.00%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- +48.3%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +74.0%
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- +70.1%
- Free cash flow
- -6.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026